Informatics on Drug Repurposing for Breast Cancer.


Journal

Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745

Informations de publication

Date de publication:
2023
Historique:
received: 17 04 2023
accepted: 17 06 2023
medline: 7 7 2023
pubmed: 5 7 2023
entrez: 5 7 2023
Statut: epublish

Résumé

Moving a new drug from bench to bedside is a long and arduous process. The tactic of drug repurposing, which solves "new" diseases with "old" existing drugs, is more efficient and economical than conventional ab-initio way for drug development. Information technology has dramatically changed the paradigm of biomedical research in the new century, and drug repurposing studies have been significantly accelerated by implementing informatics techniques related to genomics, systems biology and biophysics during the past few years. A series of remarkable achievements in this field comes with the practical applications of in silico approaches including transcriptomic signature matching, gene-connection-based scanning, and simulated structure docking in repositioning drug therapies against breast cancer. In this review, we systematically curated these impressive accomplishments with summarization of the main findings on potentially repurposable drugs, and provide our insights into the current issues as well as future directions of the field. With the prospective improvement in reliability, the computer-assisted repurposing strategy will play a more critical role in drug research and development.

Identifiants

pubmed: 37405253
doi: 10.2147/DDDT.S417563
pii: 417563
pmc: PMC10315146
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1933-1943

Informations de copyright

© 2023 Zhou et al.

Déclaration de conflit d'intérêts

H.L., Y.Y. and X.Y. are all employees of Changsha Kingmed Center for Clinical Laboratory. X.Y. is also an employee of Guangzhou Kingmed Center for Clinical Laboratory. All other authors declare no financial or non-financial competing interests in this work.

Références

Nat Rev Clin Oncol. 2015 Oct;12(10):573-83
pubmed: 26122181
Biomed Pharmacother. 2022 Jan;145:112375
pubmed: 34863612
Bioinformatics. 2018 Aug 15;34(16):2817-2825
pubmed: 29534151
Clin Cancer Res. 2022 Mar 15;28(6):1072-1086
pubmed: 34711632
Life (Basel). 2021 Oct 20;11(11):
pubmed: 34832991
Onco Targets Ther. 2013 Jul 23;6:943-55
pubmed: 23901284
Mol Inform. 2022 Aug;41(8):e2100300
pubmed: 35195941
Front Genet. 2019 May 07;10:420
pubmed: 31134131
Nature. 2020 Apr;580(7803):402-408
pubmed: 32296183
Front Mol Biosci. 2022 Sep 08;9:962799
pubmed: 36158572
Molecules. 2021 Dec 10;26(24):
pubmed: 34946556
IEEE/ACM Trans Comput Biol Bioinform. 2018 Nov-Dec;15(6):1960-1967
pubmed: 29993812
Pharmacol Rep. 2019 Jun;71(3):535-544
pubmed: 31026757
Bioinformatics. 2019 Aug 15;35(16):2818-2826
pubmed: 30624606
Cancer Metastasis Rev. 2016 Dec;35(4):575-588
pubmed: 27913999
Cancers (Basel). 2021 Dec 14;13(24):
pubmed: 34944904
Bioinformatics. 2021 Sep 29;37(18):2930-2937
pubmed: 33739367
Cancer Commun (Lond). 2020 Aug;40(8):329-344
pubmed: 32654419
Semin Cancer Biol. 2021 Jan;68:59-74
pubmed: 31562957
Front Immunol. 2021 Feb 25;12:643692
pubmed: 33717201
Cell. 2017 Nov 30;171(6):1437-1452.e17
pubmed: 29195078
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Front Pharmacol. 2018 Jun 05;9:583
pubmed: 29922160
Oncologist. 2017 Sep;22(9):1086-1093
pubmed: 28559413
Nat Methods. 2013 Dec;10(12):1209-10
pubmed: 24122041
Cell Oncol (Dordr). 2018 Dec;41(6):677-686
pubmed: 30182339
Front Pharmacol. 2019 Feb 19;10:109
pubmed: 30837876
Molecules. 2020 Nov 25;25(23):
pubmed: 33255661
Expert Opin Drug Discov. 2019 Aug;14(8):755-768
pubmed: 31146609
Pharmaceuticals (Basel). 2022 Apr 29;15(5):
pubmed: 35631382
ACS Omega. 2022 Dec 29;8(1):56-73
pubmed: 36643505
BMC Bioinformatics. 2022 Apr 20;23(1):143
pubmed: 35443626
Semin Cancer Biol. 2021 Jan;68:8-20
pubmed: 31550502
Semin Cancer Biol. 2021 Jan;68:132-142
pubmed: 31904426
Brief Bioinform. 2017 Sep 1;18(5):903
pubmed: 28334173
NPJ Syst Biol Appl. 2016;2:
pubmed: 28413689
Front Pharmacol. 2018 Aug 15;9:905
pubmed: 30158869
Mol Oncol. 2019 Oct;13(10):2259-2277
pubmed: 31408580
Mol Divers. 2022 Nov 14;:
pubmed: 36376717
Pharmaceuticals (Basel). 2021 Aug 12;14(8):
pubmed: 34451888
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Adv Exp Med Biol. 2022;1361:269-282
pubmed: 35230694
Molecules. 2020 Aug 28;25(17):
pubmed: 32872166
Nat Commun. 2023 Feb 22;14(1):993
pubmed: 36813801
Hum Mol Genet. 2016 Oct 1;25(R2):R94-R98
pubmed: 27340225
Comput Biol Chem. 2019 Jun;80:90-101
pubmed: 30939415
Int J Mol Sci. 2022 Oct 20;23(20):
pubmed: 36293493

Auteurs

Hui Zhou (H)

Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China.
Department of Lymphoma and Hematology, Hunan Cancer Hospital, Changsha, Hunan, People's Republic of China.

Hongdou Liu (H)

Department of Laboratory Diagnosis, Changsha Kingmed Center for Clinical Laboratory, Changsha, Hunan, People's Republic of China.

Yan Yu (Y)

Department of Laboratory Diagnosis, Changsha Kingmed Center for Clinical Laboratory, Changsha, Hunan, People's Republic of China.

Xiao Yuan (X)

Department of Laboratory Diagnosis, Changsha Kingmed Center for Clinical Laboratory, Changsha, Hunan, People's Republic of China.
Department of Laboratory Diagnosis, Guangzhou Kingmed Center for Clinical Laboratory, Guangzhou, Guangdong, People's Republic of China.

Ling Xiao (L)

Department of Histology and Embryology of Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH